Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of BKM120 that
can be given to patients with relapsed or refractory leukemia. The safety of BKM120 will also
be studied.